Kanagawa, Japan

Kazuhiro Ohara

USPTO Granted Patents = 2 



Average Co-Inventor Count = 10.0

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2021-2024

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):

Title: Kazuhiro Ohara: Innovator in Antigen-Binding Molecules

Introduction

Kazuhiro Ohara is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of antigen-binding molecules. With a total of two patents to his name, Ohara's work focuses on creating innovative solutions for treating various diseases.

Latest Patents

Ohara's latest patents involve antigen-binding molecules whose activity varies according to the concentration of specific compounds. The objective of his inventions is to provide target tissue-specific antigen-binding molecules. These molecules are designed to have their binding activity change depending on the concentration of unnatural compounds. His patents also include libraries of these molecules, pharmaceutical compositions, and methods for screening and producing the antigen-binding molecules. The innovative aspect of his work lies in the creation of antigen-binding domains that can treat diseases originating from target tissues in a specific manner.

Career Highlights

Kazuhiro Ohara is associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company. His work at Chugai has allowed him to focus on the development of advanced therapeutic solutions. Ohara's contributions have been instrumental in pushing the boundaries of biotechnology and improving treatment options for patients.

Collaborations

Ohara has collaborated with notable colleagues, including Tomoyuki Igawa and Shigero Tamba. These collaborations have further enhanced the research and development efforts in the field of antigen-binding molecules.

Conclusion

Kazuhiro Ohara's innovative work in the field of antigen-binding molecules showcases his dedication to advancing biotechnology. His patents reflect a commitment to developing targeted therapies that can significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…